China's Sinopharm says data 'better than expected" from unit's COVID-19 vaccine trials - (Fidelity via NewsPoints Desk)

  • China National Pharmaceutical Group (Sinopharm) said on Wednesday the data from large-scale, Phase III trials for its unit's COVID-19 vaccine are "better than expected," as reported Fidelity.

  • Sinopharm's unit China National Biotec Group has moved two vaccine candidates into Phase III trials outside China in multiple countries including the United Arab Emirates, Bahrain and Egypt involving more 50,000 participants in total.

To read more NewsPoints articles, click here.